Complex Regional Pain Syndrome (CRPS)NCT07093424
Relationship Between Complex Regional Pain Syndrome and Magnesium Depletion Score
An observational study of Complex Regional Pain Syndrome (CRPS), run by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization at 1 site in Turkey (Türkiye).
Trial summary
Complex Regional Pain Syndrome (CRPS) is a condition triggered by trauma such as surgery or a fracture. It is characterised by pain and limited mobility that are disproportionate to the severity of the trauma and the clinical course. Magnesium is recognised for its anti-inflammatory and antioxidant properties. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Complex Regional Pain Syndrome (CRPS)
- What is being tested?
- scoring
- How many people
- 117 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2025to 1 Jun 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients admitted to our hospital's physical therapy and rehabilitation outpatient clinics with traumatic extremity injuries
Who may be able to join
- Male and female patients aged 18-99 years with traumatic extremity injuries
Who cannot join
- History of previous stroke, spinal cord injury
- Presence of radiculopathy, radicular pain in the affected extremity
- Previous surgery for cervical discopathy/lumbar discopathy
- Presence of oncological, haematological diseases
- History of previous peripheral nerve injury or previous surgery
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Prof. Dr. Cemil Taşçıoğlu Şehir Hastanesi
Şişli, Istanbul
About this study
Official title: The Relationship of Magnesium Depletion Score With the Development of Complex Regional Pain Syndrome in Patients With Traumatic Extremity Injury
Complex Regional Pain Syndrome (CRPS) is a condition triggered by trauma such as surgery or a fracture. It is characterised by pain and limited mobility that are disproportionate to the severity of the trauma and the clinical course. Magnesium is recognised for its anti-inflammatory and antioxidant properties. The magnesium depletion score (MDS) is a more reliable and comprehensive scoring tool than measuring serum and urine magnesium levels. This score takes into account the patient's use of diuretics and proton pump inhibitors, their alcohol consumption, and their glomerular filtration rate. Impaired magnesium distribution may be a risk factor for CRPS development due to increased nociceptor activity. This study aimed to investigate whether an increased MDS score is a risk factor for CRPS development in individuals with traumatic limb injury.
- Conditions
- Complex Regional Pain Syndrome (CRPS)
- Being tested
- scoring
- Medical subject headings
- Complex Regional Pain Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
scoringOther
magnesium depletion score calculation
| Study group | Role | What they receive |
|---|---|---|
| traumatic extremity injury | Not described Receives: Other: scoring |
What is being measured
The primary outcome is the main question the study is designed to answer.
CRPS development
crps development will be assessed according to Budapest criteria
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2025
- Study start1 Jan 2025
- Primary completion1 Jan 2025
- Study completion1 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Complex Regional Pain Syndrome (CRPS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 117 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dilara Ekici Zincirci, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07093424
- Sponsor's protocol ID
- RSD1
- Status last verified
- Mar 2025
- First submitted
- 30 Jun 2025
- Last updated
- 30 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: only IPD used in the results publication
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Relationship of Magnesium Depletion Score With the Development of Complex Regional Pain Syndrome in Patients With Traumatic Extremity Injury
- ClinicalTrials.gov ID
- NCT07093424
- Acronym / sponsor ID
- RSD1
- Conditions
- Complex Regional Pain Syndrome (CRPS)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 117 participants (actual)
- Lead sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital OrganizationUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 1 Jun 2025 (actual)
- First posted
- 30 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Complex Regional Pain Syndrome (CRPS) is a condition triggered by trauma such as surgery or a fracture. It is characterised by pain and limited mobility that are disproportionate to the severity of the trauma and the clinical course. Magnesium is recognised for its anti-inflammatory and antioxidant properties. The magnesium depletion score (MDS) is a more reliable and comprehensive scoring tool than measuring serum and urine magnesium levels. This score takes into account the patient's use of diuretics and proton pump inhibitors, their alcohol consumption, and their glomerular filtration rate. Impaired magnesium distribution may be a risk factor for CRPS development due to increased nociceptor activity. This study aimed to investigate whether an increased MDS score is a risk factor for CRPS development in individuals with traumatic limb injury.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| traumatic extremity injury | – | Other: scoring |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients admitted to our hospital's physical therapy and rehabilitation outpatient clinics with traumatic extremity injuries
Key inclusion criteria (1 listed)
- Male and female patients aged 18-99 years with traumatic extremity injuries
Key exclusion criteria (5 listed)
- History of previous stroke, spinal cord injury
- Presence of radiculopathy, radicular pain in the affected extremity
- Previous surgery for cervical discopathy/lumbar discopathy
- Presence of oncological, haematological diseases
- History of previous peripheral nerve injury or previous surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| scoringmagnesium depletion score calculation | Other | traumatic extremity injury |
Primary outcome
CRPS development
Time frame: baseline
crps development will be assessed according to Budapest criteria
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2025.
- Individual participant dataSharing planned: Yes. only IPD used in the results publication
Related trials for Complex Regional Pain Syndrome (CRPS)
Enrolling by invitationPhase 4
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Complex Regional Pain Syndrome, Chronic Pain
RecruitingPhase 3
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Complex Regional Pain Syndrome Type I
Recruiting
The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.
CRPS (Complex Regional Pain Syndromes)
RecruitingPhase 3
Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1
Complex Regional Pain Syndrome Type I
Active, not recruiting
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
Chronic Neuropathic Pain, Post-Stroke Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Complex Regional Pain Syndrome (CRPS), run by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CRPS development (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2025.